Excretion of Paroxetine Into Breast Milk

Ohman, R; Hägg, Staffan; Carleborg, Lena; Spigset, Olav

doi:10.4088/jcp.v60n0803

Cited by 78 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In several instances, when the mother was receiving therapeutic doses of SSRI. the concentration of the drug in the infant was minimal or undeteetable for fluoxetine (67)(68)(69)(70)(71)(72)(73)(74), paroxetine (75)(76)(77)(78)(79), sertraline (74,79 81,83-85,87). fluvoxamine (75,(89)(90)(91)(92) or citalopram (93)(94)(95)(96)(97), Moreover, when mother was taking therapeutic doses of sertraline, serotonin transporter bloekade in the fetus was found to be far lower than would be expected from that observed in the mother, suggesting that clinical doses of sertraline in the mother do not appreciably affect the fetus (81).…”

Section: Amidepressants and Breastfeedingmentioning

confidence: 99%

Pharmacotherapy of Depression in Pregnancy

Patkar¹,

Bilal²,

Masand³

2004

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

About 20% of pregnant women experience clinical depression. Inadequate treatment of depression has been associated with adverse outcomes in the mother as well as the newborn. Clinicians are often uncertain about pharmacological interventions to treat depressed pregnant women due to concerns regarding fetal exposure to medications. Moreover newer antidepressants with different pharmacological profiles and little data on fetal risk continue to be introduced at a brisk pace. Accumulating data from pharmaceutical registries, cohort studies, toxicology centers, some prospective studies, and case series have permitted certain guidelines for antidepressant use during pregnancy. We review the safety profiles of commonly used antidepressants, discuss clinical decision making based on risk-benefit considerations and make recommendations for pharmacological treatment of depressed women during pregnancy.

show abstract

Section: Amidepressants and Breastfeedingmentioning

confidence: 99%

Pharmacotherapy of Depression in Pregnancy

Patkar¹,

Bilal²,

Masand³

2004

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

show abstract

“…Serotonin selective uptake inhibitors are highly lipidsoluble compounds and cross the placenta as well as are excreted to breast milk; however, in humans the relative concentration to a suckling infant for fluoxetine is higher than others SSRIs (Ohman et al, 1999;Spigset et al, 1997). Pharmacological evidence demonstrated also that the elevation of the cerebral levels of 5-HT affects the secretion of FSH and luteinizing hormone (LH), for inhibiting the liberation of gonadotrophins releasing factor (GnRH) in the hypothalamus, with subsequent effects on the process of spermatogenesis and steroidogenesis in adult rats (Das et al, 1982(Das et al, , 1985Naumenko & Shishkina, 1978;Urry & Dougherty, 1975).…”

Section: Introductionmentioning

confidence: 99%

Neonatal Administration of Fluoxetine Decreased Final Sertoli Cell Number in Wistar Rats

Silva

Amorim

et al. 2008

Int. J. Morphol.

View full text Add to dashboard Cite

SUMMARY:The aim of the present study was to test the hypothesis that the application of fluoxetine -a highly selective serotonin reuptake inhibitor (SSRI) -in rats during the suckling period induces changes in testicular development. Groups of newborn male rats were randomly assigned with different doses of fluoxetine 24 hours after birth. Each litter stayed with its respective mother during 21 days. Body weight (BW) was measured daily from the 1st -21 st day to calculate daily doses of fluoxetine. 5 mg (T1), 10 mg (T2) 20 mg (T3) or deionized water, were injected intraperitoneally. On the 21 st day, animals were heparinized, anesthetized and blood was collected by cardiac puncture to determine by radioimmunoassay the follicle stimulating hormone (FSH) levels. Testis were removed, weighed, and processed for morphometric analysis. Fluoxetine groups presented decreased body and testicular weight when compared with the control group on the 21 st day. Our findings show that the manipulation of the serotoninergic system with fluoxetine during the critical period of testicular development alters the Sertoli cell population and all testicular parameters related to this cell.

show abstract

“…(J Clin Psychopharmacol 2005;25: [59][60][61][62][63][64][65][66][67][68][69][70][71][72][73] A n estimated 8% to 20% of all women develop clinical symptoms of depression at some time during their lives, for which drug therapy is often required. 1,2 In addition, mood disorders and anxiety disorders such as depression, panic disorder, and obsessive-compulsive disorder are common in women during their childbearing years, 3 which increases the likelihood of potential need for antidepressants during pregnancy.…”

mentioning

confidence: 99%

The Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and Breast-feeding

Hallberg

Sjöblom

2005

Journal of Clinical Psychopharmacology

106

View full text Add to dashboard Cite

Mood and anxiety disorders are common in women during their childbearing years. The prevalence of depression has been reported to be between 10% and 16% during pregnancy. The use of selective serotonin reuptake inhibitors during pregnancy or lactation is, to date, not promoted because of lack of safety documentation. However, the off-label use of these drugs has been common for several years. In the treatment of mood and anxiety disorders during pregnancy, the serotonin reuptake inhibitors are often preferred over tricyclic antidepressants because of their relatively few adverse effects and safety in overdose. This has created concern among women planning pregnancies and pregnant women, as well as among their families and physicians. Several studies and reports of the use of serotonin reuptake inhibitors during both pregnancy and lactation have been published and advanced our knowledge. We here review and discuss those studies which have been published so far on this subject.

show abstract

Excretion of Paroxetine Into Breast Milk

Cited by 78 publications

References 0 publications

Pharmacotherapy of Depression in Pregnancy

Pharmacotherapy of Depression in Pregnancy

Neonatal Administration of Fluoxetine Decreased Final Sertoli Cell Number in Wistar Rats

The Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and Breast-feeding

Contact Info

Product

Resources

About